Scully et al. performed a prospective, observational study with 34 adults with at least one Phe508del mutation and a history of exocrine pancreatic insufficiency, in which they used continuous glucose monitoring (CGM) sensors for 14 days before ELX/TEZ/IVA initiation and 3–12 months after therapy, with the purpose of assessing the effect of the triple CFTR modulator treatment on glycemic status (50% of the participants had already had CFRD). This evidence concerns the gene CFTR and exocrine pancreatic insufficiency.